Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00773955 · ClinicalTrials.gov registry record · Phase 2
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
A Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00773955 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00773955, a Phase 2 study of Extensive-stage Small-cell Lung Cancer and Recurrent Small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well R-(-)-gossypol acetic acid works in treating patients with recurrent extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as R-(-)-gossypol acetic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG R-(-)-gossypol acetic acid
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00773955
The ClinicalTrials.gov registry entry for NCT00773955 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (91% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00773955 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00773955 about?
NCT00773955 is a clinical study titled "R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer". This phase II trial is studying how well R-(-)-gossypol acetic acid works in treating patients with recurrent extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as R-(-)-gossypol acetic acid, work in different ways to stop the growth of tumor cells, either by killing the cells ...
What is the current status of trial NCT00773955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-11. Estimated completion is 2010-08.
What conditions does trial NCT00773955 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer, Recurrent Small Cell Lung Cancer.
What interventions are being tested in trial NCT00773955?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), R-(-)-gossypol acetic acid (DRUG).
Who is sponsoring clinical trial NCT00773955?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00773955 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
RECRUITING · Phase 2
-
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 2
-
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
ACTIVE NOT RECRUITING · Phase 2
-
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Extensive-stage Small-cell Lung Cancer
All registered trials for this condition
Recurrent Small Cell Lung Cancer
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.